Retrospective observational study shows acceptable safety of colistin treatment in neonates with late-onset sepsis, suggesting careful monitoring is necessary.
Key Points
Colistin treatment demonstrates an acceptable short-term safety profile in critically ill neonates with late-onset sepsis, highlighting its viability as a treatment option.
Serum creatinine levels showed similar alterations within the first 7 days of colistin treatment, with moderate evidence supporting its safety.
A retrospective case-control analysis compared 58 critically ill neonates treated with colistin to 22 controls, assessing renal function and electrolyte levels.
Routine monitoring of renal function and electrolytes is emphasized to mitigate potential complications of colistin therapy in the neonatal ICU.